Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer ...
A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results